Bladder Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Bladder Cancer stocks.

Bladder Cancer Stocks Recent News

Date Stock Title
May 14 ACRV Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 14 URGN UroGen Pharma First Quarter 2024 Earnings: Misses Expectations
May 13 URGN UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript
May 13 URGN UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations
May 13 TYRA Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
May 13 URGN UroGen Pharma GAAP EPS of -$0.97 misses by $0.08, revenue of $18.78M misses by $2.61M
May 13 URGN UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
May 12 URGN Shareholders in UroGen Pharma (NASDAQ:URGN) have lost 67%, as stock drops 11% this past week
May 10 EVAX Evaxion receives Nasdaq notification over minimum stockholders’ equity requirement
May 10 EVAX Evaxion Receives Nasdaq Notification
May 10 URGN UroGen Pharma Q1 2024 Earnings Preview
May 10 ACRV Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season?
May 10 TYRA Tyra Biosciences GAAP EPS of -$0.35 beats by $0.11
May 10 NEO NeoGenomics Earnings Analysis: Q1 Recap
May 10 FUSN Fusion Pharmaceuticals doses first subject in prostate cancer trial
May 9 FUSN Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
May 9 TYRA Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
May 9 ACRV While institutions own 26% of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), private equity firms are its largest shareholders with 50% ownership
May 8 BCAB BioAtla to Participate in the Citizens JMP Life Sciences Conference
May 7 TYRA Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors
Bladder Cancer

Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. It is a disease in which cells grow abnormally and have the potential to spread to other parts of the body. Symptoms include blood in the urine, pain with urination, and low back pain.Risk factors for bladder cancer include smoking, family history, prior radiation therapy, frequent bladder infections, and exposure to certain chemicals. The most common type is transitional cell carcinoma. Other types include squamous cell carcinoma and adenocarcinoma. Diagnosis is typically by cystoscopy with tissue biopsies. Staging of the cancer is typically determined by medical imaging such as CT scan and bone scan.Treatment depends on the stage of the cancer. It may include some combination of surgery, radiation therapy, chemotherapy, or immunotherapy. Surgical options may include transurethral resection, partial or complete removal of the bladder, or urinary diversion. Typical five-year survival rates in the United States are 77%.Bladder cancer, as of 2015, affects about 3.4 million people globally with 430,000 new cases a year. In 2015 it resulted in 188,000 deaths. Age of onset is most often between 65 and 85 years of age. Males are more often affected than females. In the United States in 2018 81,000 cases and 17,000 deaths are expected making it the 6th most common type of cancer in the region.

Browse All Tags